NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Ovid Therapeutics Inc. (OVID) Stock Analysis

Ovid Therapeutics Inc. (OVID) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

OVID

$2.47

+$0.11 (+4.66%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OVID with… →

OVID Key Statistics

As of Oct 21, 2026
Trading
Open
$2.35
Previous Close
$2.36
Day's Range
2.35–2.65
52-Week Range
1.18–3.11
Volume
5.00M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.23
Valuation
Market Cap
$482.39M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
304.73
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.22
Financials (FY)
Revenue (FY)
$7.25M+1,181.27%
Net Income (FY)
−$17.41M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
195.30M
1-Year Return
+54.38%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
1.62M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, OVID closed at $2.47, +54.38% over 1 year.

Ovid Therapeutics Inc. (OVID) has a market capitalization of $482.39M.

In fiscal 2025, OVID reported revenue of $7.25M.

OVID Stock Return by Calendar Year

Ovid Therapeutics Inc. (OVID) return since May 2017: what $10,000 became

1 year
$10,000 $15,438
+54.38%
5 years
$10,000 $6,823
−31.77%
Since May 2017
$10,000 $2,016
−79.84%

If you had invested $10,000 in Ovid Therapeutics Inc. (OVID) at the close on May 5, 2017, the earliest close on record here, it would have been worth $2,016 at the close on October 21, 2026: −79.84% in total, −15.57% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+51.53%
2025+74.52%
2024−70.99%
2023+73.12%
2022−42.06%
2021+38.96%
2020−44.34%
2019+71.49%
2018−75.48%
2017 (partial year)−19.43%

As of October 21, 2026.

OVID Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.25M−$17.41M−240.1%
2024$566.00K−$26.43M−4,670.1%
2023$392.00K−$52.34M−13,351.8%
2022$1.50M−$54.17M−3,604.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.25M—−$42.44M−$17.41M−240.1%
2024$566.00K—−$61.89M−$26.43M−4,670.1%
2023$392.00K—−$59.28M−$52.34M−13,351.8%
2022$1.50M—−$55.55M−$54.17M−3,604.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OVID Valuation vs Biotechnology Median

Median of 608 stocks
MetricOVIDBiotechnology medianvs median
P/S ratio304.7313.3022.9x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Ovid Therapeutics Inc. (OVID) is capitalised at $482.39M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 23 employees.

The 52-week range on file runs from $1.18 to $3.11. The most recent close on file for OVID is $2.47, dated October 21, 2026. That is +$0.11 (+4.66%) against the previous close. The latest close sits 109.32% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $7.25M. Against the prior fiscal year total of $566.00K, that is a change of +1,181.27%. The same year closed with a net loss of $17.41M. Earnings per share on a trailing basis come to −0.22.

Across the 4 fiscal years on file, revenue moves from $1.50M in 2022 to $7.25M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 304.73. On price-to-sales that is 22.9 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 0.23. Annualized volatility over the trailing 9 years is 84.38%. The trailing one-year total return is +54.38%. Measured over 5 years, that is −7.36% a year compounded.

Growth & Income

No dividend is on file for OVID.

So far in 2026 the total return is +51.53%. The strongest complete calendar year on file is 2025 at +74.52%; the weakest is 2018 at −75.48%. Of the 8 complete calendar years on file, 4 finished higher.

Peer Comparison

Ovid Therapeutics Inc. (OVID) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ovid Therapeutics Inc. OVID $482.39M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Ovid Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Visit website →